CCG-100602

CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells (IC50 :9.8 µM) .

1207113-88-9

≥ 2 years

>98% (HPLC)

478.82

C21H17ClF6N2O2

Research use only, not for human use.

Rho

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

HP228420 200 Reactions

Ask

NBP2-97822V 0.1 mL

Ask

ABP60329-01 30 µL

Ask

ABP60329-02 100 µL

Ask

ABP60329-03 200 µL

Ask

MBS1300038-01 0.02 mg (E-Coli)

Ask